Silverleafe Capital Partners’s Pfizer PFE Stock Holding History

Silverleafe Capital Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,174	Closed	-$214K	–	59
2022 Q4	$214K	Buy	+4,174	New	+$200K	0.14%	51
2022 Q3	–	Sell	-4,174	Closed	-$219K	–	69
2022 Q2	$219K	Sell	4,174 -532	-11%	-$27.1K	0.13%	56
2022 Q1	$244K	Buy	4,706 +1,066	+29%	+$55.3K	0.11%	60
2021 Q4	$215K	Buy	+3,640	New	+$180K	0.08%	81
2019 Q3	–	Sell	-55,789	Closed	-$2.29M	–	71
2019 Q2	$2.29M	Sell	55,789 -6,045	-10%	-$240K	1.38%	19
2019 Q1	$2.49M	Buy	61,834 +4,231	+7%	+$169K	1.48%	21
2018 Q4	$2.39M	Buy	57,603 +8,577	+17%	+$356K	1.64%	19
2018 Q3	$2.05M	Sell	49,026 -1,532	-3%	-$59K	1.25%	24
2018 Q2	$1.74M	Sell	50,558 -6,056	-11%	-$207K	1.09%	25
2018 Q1	$1.91M	Sell	56,614 -1,271	-2%	-$43.7K	1.26%	23
2017 Q4	$1.99M	Buy	+57,885	New	+$1.97M	1.34%	23

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Silverleafe Capital Partners's PFE Position: Q1 2023 in Review

Silverleafe Capital Partners sold out of Pfizer (PFE) in Q1 2023, closing a stake of 4,174 shares — an estimated $214K sold.

Silverleafe Capital Partners first reported a position in PFE in Q4 2017 and held it in 11 quarters. The position peaked at $2.49M in Q1 2019. 3,102 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

Silverleafe Capital Partners reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
Silverleafe Capital Partners sold 4,174 Pfizer shares in Q1 2023, an estimated $214K.
Silverleafe Capital Partners first reported a position in Pfizer in Q4 2017 and held it in 11 quarters.
Silverleafe Capital Partners's Pfizer position peaked at $2.49M in Q1 2019.
3,102 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on Silverleafe Capital Partners's 13F filing for Q1 2023, filed 6 Apr 2023.